Hormone replacement therapy and breast cancer: A qualitative review

Obstetrics and Gynecology

Volumn 98, Issue 3, 2001, Pages 498-508

  Bush, Trudy L ^a   Whiteman, Maura ^a   Flaws, Jodi A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; GESTAGEN; INHIBIN A; INHIBIN B; PRASTERONE; PROGESTERONE; TAMOXIFEN;

BREAST CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMPETITIVE INHIBITION; DATA BASE; DISEASE ASSOCIATION; DRUG EFFECT; ENDOMETRIUM CARCINOMA; EPIDEMIOLOGICAL DATA; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; META ANALYSIS; OVARIECTOMY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

BREAST NEOPLASMS; CAUSALITY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; RISK ASSESSMENT;

EID: 0034825795     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(01)01453-3     Document Type: Review

References (100)

1. Association of exogenous estrogen and endometrial carcinoma
2. The risk of endometrial and breast cancer after estrogen treatment. A review of epidemiological studies
3. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: Review
4. Estrogens and endometrial cancer in a retirement community
5. Endometrial carcinoma: Histopathology, survival, and exogenous estrogens
6. Exogenous estrogens and development of breast and endometrial cancer
7. Estrogens and endometrial cancer: Fact or fiction?
8. Estrogens and endometrial cancer: Some answers and some further questions
9. Estrogen and endometrial cancer: Cases and two control groups from North Carolina
10. The relationship of exogenous estrogens to cancer risk
11. Case-control study of endogenous steroid hormones and endometrial cancer
12. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study
13. Effects of long-term estrogen replacement therapy II. Neoplasia
14. Increasing incidence of endometrial cancer in the United States
15. Exogenous estrogens and endometrial carcinoma: Review and comments for the clinician
16. Relationship of estrogens and oral contraceptives to endometrial cancer in animals and women
17. Predominance of early endometrial cancers after long-term estrogen use
18. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens
19. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues
20. Conjugated estrogen use and risk of endometrial cancer
21. Reserpine and breast cancer in a retirement community
22. Menopausal estrogens and breast cancer
23. Brief communication: Exogenous estrogens and breast cancer in women with natural menopause
24. The epidemiology of breast cancer in 785 United States caucasian women
25. Replacement estrogens and breast cancer
26. A case-control study of menopausal estrogen therapy and breast cancer
27. Conjugated estrogens and breast cancer risk in women
28. Exogenous estrogens and other factors in the epidemiology of breast cancer
29. Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases
30. Breast cancer and estrogen replacement therapy
31. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users
32. Estrogen use and breast cancer. Interaction with body mass
33. Noncontraceptive estrogen use and the risk of breast cancer
34. Effect of clinical features on the association of estrogens and breast cancer
35. Exogenous estrogen and breast cancer after bilateral oophorectomy
36. The association of replacement estrogens with breast cancer
37. Menopausal estrogen use and the risk of breast cancer
38. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy
39. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy
40. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark
41. Non-contraceptive exogenous oestrogen therapy and breast cancer
42. Prospective study of exogenous hormone use and breast cancer in seventh-day adventists
43. The risk of breast cancer after estrogen and estrogen-progestin replacement
44. Estrogen replacement therapy and the risk of breast cancer: Results from the Case-Control Surveillance Study
45. Breast cancer risk after estrogen replacement therapy: Results from the Toronto Breast Cancer Study
46. Breast cancer risk: Effects of estrogen replacement therapy and body mass
47. Noncontraceptive hormone use and risk of breast cancer
48. Oestrogen replacement therapy and breast cancer risk: A case control study
49. Menopausal hormone usage and breast cancer in Saskatchewan: A record-linkage cohort study
50. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
51. Hormone replacement treatment and breast cancer risk: Cooperative Italian study
52. Oral contraceptives, menopausal estrogens, and the risk of breast cancer: A case-control study in Greece
53. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women
54. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women
55. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening
56. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy
57. Postmenopausal estrogen use and invasive versus in situ breast cancer risk
58. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)
59. Estrogen replacement therapy in women with a history of proliferative breast disease
60. Breast cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy
61. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement
62. Hormone replacement therapy and breast cancer risk in a nationally representative cohort
63. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
64. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
65. Menopausal hormones and breast cancer in a biracial population
66. Exogenous hormone use and the risk of postmenopausal breast cancer: Results from the Netherlands Cohort Study
67. Oral contraceptives, menopausal hormone replacement therapy and breast cancer risk
68. Risk factors for breast carcinoma in Singaporean Chinese women: The role of central obesity
69. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
70. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy
71. Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis
72. Decreased mortality in users of estrogen replacement therapy
73. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States
74. Postmenopausal hormone therapy and mortality
75. Estrogen replacement therapy and breast cancer survival in a large screening study
76. Menopausal estrogen replacement therapy and breast cancer
77. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies
78. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
79. Breast cancer risk and duration of estrogen use: The role of study design in meta-analysis
80. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
81. Menopausal hormone replacement therapy and breast cancer: A meta-analysis
82. Point/counterpoint: Meta-analysis of observational studies. Meta-analysis/Shmeta-analysis
83. Spurious precision? Meta-analysis of observational studies
84. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women
85. Hormone replacement therapy and risk of breast cancer with a favorable histology. Results of the Iowa Women's Health Study
86. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy
87. Clinical and biological prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy
88. Hormone replacement therapy and breast cancer risk
89. Postmenopausal hormone replacement therapy: Effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation
90. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients
91. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)
92. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women
93. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases
94. Reproductive factors and breast cancer
95. Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurse's Health Study
96. Breast cancer diagnosed during hormone replacement therapy
97. Hormone replacement therapy and tumour grade in breast cancer: Prospective study in screening unit
98. Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause
99. The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer